Wood Violet Fertility LLC acquires Family Beginnings P.C. for USD 400,000 (2026)

Deal facts

Buyer: Wood Violet Fertility LLC
Target: Family Beginnings P.C.
Deal value: USD 400,000
Announced: 24 February 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

18 Feb 2026CompletedClosed
Wood Violet Fertility LLC completes acquisition of Family Beginnings P.C.
Item 1.01. Entry into a Material Definitive Agreement. Closing of Family Beginnings P.C. Acquisition As described in further detail under Item 2.01 below, on February 18, 2026, INVO Fertility Inc., a Nevada corporation (the “Company”), consummated the acquisition of the Clinic (as defined under Item 2.01 below) by, Wood Violet Fertility LLC, a Delaware limited liability company (“Buyer”) and wholl
Source

OpinionExit Mode editorial

We see a clear signal in the US healthcare sector where Wood Violet Fertility LLC has completed its acquisition of Family Beginnings P.C. for 400,000 USD. The deal closed on 24 February 2026 and was structured entirely as a share exchange. This is not a cash-out exit for the sellers. Instead, the transaction converts the target into a wholly owned subsidiary while retaining the economic upside within the combined entity. For the SME founder reading this, the mechanics of a pure share deal in a completed transaction mean you have traded immediate liquidity for a long-term stake in a larger platform.

The strategic logic here is straightforward consolidation within fertility services. By acquiring Family Beginnings P.C., Wood Violet Fertility LLC is expanding its clinical footprint without the friction of a cash-heavy purchase. The use of shares as the sole consideration suggests the buyer values the target's team and patient base enough to keep the founders aligned with future performance. This structure often triggers change-of-control covenants in existing lender agreements or lease contracts, requiring immediate review of all commercial terms. In the US healthcare context, such moves also invite scrutiny under anti-trust thresholds if the combined entity holds significant local market share, though a deal of this size may fall below federal reporting requirements.

We think this approach highlights a broader trend where buyers prefer to preserve founder equity to ensure continuity of care and operational stability. The risk for the seller is the dilution of control and the uncertainty of the combined entity's future value. Since the deal is already completed, the regulatory clearance phase is behind them, but the integration phase now begins. The absence of cash consideration means the former owners must trust the buyer's capital structure and growth strategy implicitly. This is a common trade-off in private equity roll-ups or strategic consolidations where the goal is scale rather than immediate payout.

Your immediate task this week is to audit your own commercial contracts for change-of-control clauses before you even speak to a potential buyer. Many founders ignore these until a term sheet arrives, only to find their lease or lender agreement forces an unwanted termination or penalty. Identify which agreements require third-party consent if your company is acquired, and prepare a mitigation plan now so you do not lose leverage during negotiations.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Wood Violet Fertility LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history